CJC-1295 and ipamorelin can prompt your pituitary gland to release growth hormone. That lab result does not mean the pair builds steroid-like muscle, keeps hormone levels untouched, or works in two weeks. Most CJC-1295 ipamorelin myths stretch a short hormone study into a daily-life promise.
Both molecules are synthetic peptides, which are short laboratory-made chains of protein building blocks. CJC-1295 copies part of growth hormone-releasing hormone (GHRH), a natural brain signal. Ipamorelin activates a separate switch called the ghrelin receptor.
CJC-1295 ipamorelin myths: what the grades mean
The grade supported means human studies back the claim as stated. The grade partly means one piece holds up, while the rest outruns the data. The grade not supported means the claim exceeds published findings, and unknown means the question remains untested.
1. “It's natural HGH.”
Partly: the growth hormone released into your blood comes from your own pituitary, a small gland beneath the brain. Still, both injected peptides are synthetic signals, not human growth hormone (HGH).
In two 2006 trials in The Journal of Clinical Endocrinology & Metabolism, healthy adults aged 21 to 61 received long-acting CJC-1295 or placebo. They were followed for 28 or 49 days.
After one injection, average growth hormone rose two- to tenfold for at least six days. Average IGF-1, a liver hormone that tracks growth-hormone activity, rose 1.5- to threefold for 9 to 11 days.
2. “It keeps GH rhythm completely unchanged.”
Partly: the body releases growth hormone in brief bursts, called pulses. In a December 2006 overnight study, healthy men aged 20 to 40 kept their pulse frequency and size one week after long-acting CJC-1295.
Even so, their total hormone exposure shifted upward. Baseline growth hormone between pulses jumped 7.5-fold, average growth hormone rose 46%, and IGF-1 rose 45%. That trial tested permanent albumin-binding CJC-1295 alone, not the blend.
3. “Ipamorelin can never change cortisol or prolactin.”
Partly: ipamorelin's selective reputation comes from animal data, not long-term human trials. In a 1998 European Journal of Endocrinology study, researchers tested conscious pigs at exposures over 200 times the effective growth-hormone dose. Cortisol and ACTH responses did not differ significantly from GHRH responses.
Prolactin stayed unchanged across every growth-hormone trigger tested in those pigs, so ipamorelin was not unique. A 1999 human infusion study gave healthy men intravenous ipamorelin across five exposure levels, with eight men per level. It tracked a single growth-hormone episode and did not measure long-term cortisol or prolactin in people.
4. “The pair has already been tested together in people.”
Not supported: the published human intervention studies identified in the October 17, 2026 searches tested the ingredients separately; none tested the pair. Searches of PubMed and the ClinicalTrials.gov study registry on October 17, 2026 found zero human intervention trials of the pair. PubMed returned 12 records, all reviews or doping-detection papers.
Pairing two receptor pathways has a clear rationale, which our CJC-1295 and ipamorelin guide explains. Whether combining them improves clinical outcomes or proves safe long term remains unknown.
5. “With DAC and without DAC are interchangeable.”
Not supported: DAC stands for drug affinity complex, a chemical tag that binds CJC-1295 to albumin protein in the blood. Half-life is the time it takes the level in the blood to fall by half. The DAC form had an estimated human half-life of 5.8 to 8.1 days.
In a November 2024 FDA staff assessment, reviewers noted that CJC-1295 and CJC-1295 DAC are distinct active moieties, or core drug molecules. No human study sets an exact half-life for CJC-1295 without DAC, and neither form is proven better for outcomes. Which form a compounded blend uses is a question to confirm with the prescriber.
6. “It builds muscle like an anabolic steroid.”
Not supported: higher hormone numbers on a lab test do not prove muscle growth or strength gains. Neither the 2006 CJC-1295 trials nor the 1999 ipamorelin study measured muscle or strength.
As of October 17, 2026, the day this article was written, an August 11, 2026 sports-medicine review mapped studies across six emerging peptides. Across those six compounds, including CJC-1295 and ipamorelin, 67% of papers used animal models, leaving human muscle and recovery claims unsubstantiated. Our CJC-1295 and ipamorelin for muscle growth review covers that gap.
7. “Stimulating your own GH cannot affect blood sugar.”
Not supported: growth hormone works against insulin, which clears glucose from the blood. A 2018 review in European Journal of Endocrinology notes that adult growth-hormone replacement can cause fluid retention and insulin resistance. Those effects are reversible and dose-dependent, and insulin resistance means insulin works less effectively.
That is an indirect pathway concern rather than a trial-measured diabetes rate for this blend. FDA's 2024 CJC-1295 review also reports no consistent glucose changes in the short human studies, so both facts belong together.
8. “A prescription means the blend is an approved drug.”
Not supported: neither ingredient belongs to an approved drug, per FDA's August 2024 ipamorelin review and November 2024 CJC-1295 review. CJC-1295 and ipamorelin are not FDA-approved, and a compounded blend is different from an FDA-approved product: the formulation offered here is not FDA-approved. Standalone CJC-1295 and ipamorelin are coming soon to Promise, and the formulations Promise will offer will not be FDA-approved.
On FDA's April 22, 2026 safety page, CJC-1295 sits in the nominated-but-withdrawn table, while ipamorelin acetate appears there and in 503B Category 2. Neither peptide appears in Categories 1, 2, or 3 of FDA's May 14, 2026 503A nominations list. Official minutes from October 29, 2024 and December 4, 2024 record advisory votes on 503A listing:
| Ingredient reviewed | Meeting date | Advisory vote (Yes–No–Abstain) |
|---|---|---|
| Ipamorelin free base & acetate (2 votes) | October 29, 2024 | 0–12–1 each |
| Four CJC-1295 forms (free base & 3 DAC forms) | December 4, 2024 | 0–13–0 each |
| CJC-1295 acetate | December 4, 2024 | 1–12–0 |
FDA's safety summary identifies serious adverse events associated with CJC-1295, including increased heart rate and a whole-body blood-vessel-widening reaction. It also notes limited clinical data and potential immune-response risks for certain administration routes.
For ipamorelin, FDA cites insufficient route data and a published gastric-motility study reporting serious events including death after intravenous use. Even with those records, a licensed provider may still prescribe — that decision is between you and your doctor.
9. “A prescription makes it permitted in tested sport.”
Not supported: a medical prescription does not clear a prohibited substance for competition. Both CJC-1295 and ipamorelin are prohibited at all times under section S2.2.4 of WADA's 2026 Prohibited List.
As of October 17, 2026, the day this article was written, WADA's September 21, 2026 release announced its updated rules. The 2027 Prohibited List takes effect January 1, 2027. Both peptides remain prohibited in and out of competition unless an athlete receives a separate Therapeutic Use Exemption.
10. “Visible or felt results are established within two weeks.”
Not supported: rapid blood-marker changes do not set a two-week calendar for sleep, fat loss, or recovery. In the 1999 infusion study, growth hormone peaked at 0.67 hours after intravenous ipamorelin. In the 2006 CJC-1295 trials, repeated doses kept mean IGF-1 elevated for up to 28 days, with no serious adverse reactions reported.
Sermorelin is a related GHRH option, and FDA's March 4, 2013 notice found discontinued Geref products were not withdrawn for safety or effectiveness reasons. Following 2008 discontinuation notices, Geref's withdrawal took effect June 18, 2009, and sermorelin is also prohibited under WADA S2.2.4. Today's compounded sermorelin is not FDA-approved, and it is different from the FDA-approved sermorelin product that was once marketed and has since been discontinued.
What a prescription conversation can settle
A medical evaluation separates blood-marker shifts from realistic personal goals. A clinician reviewing a request for CJC-1295 and ipamorelin may consider health history, current medications, blood-sugar context, and whether laboratory testing is needed.
At Promise, a licensed provider reviews every request and not everyone qualifies. CJC-1295 and ipamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. The reviewing clinician sets all treatment and monitoring details.
